Advertisement

Topics

Sarepta Preps For Sales As Insurers Unlikely To Deny Duchenne Drug

13:43 EDT 22 Sep 2016 | Xconomy

Kathryn Wagner treats boys with Duchenne muscular dystrophy, a rare and fatal genetic disease. She thinks the first drug ever approved to treat Duchenne is “horrendously expensive,” and she’s not comfortable with the data that the FDA said was good enough to merit the approval, which was announced with great controversy this week. But Wagner […]

Original Article: Sarepta Preps For Sales As Insurers Unlikely To Deny Duchenne Drug

NEXT ARTICLE

More From BioPortfolio on "Sarepta Preps For Sales As Insurers Unlikely To Deny Duchenne Drug"

Quick Search
Advertisement
 

Relevant Topics

Muscular Dystrophy
Muscular dystrophy is a group of degenerative inherited disorders causing muscle weakness and loss of muscle tissue. The different types are Becker muscular dystrophy, Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral mu...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...